CClinicalTrials.gg
Not yet recruitingNCT07731451Updated Jul 28, 2026

The Role of Brain Lactate Metabolism in Neuroprotection During Healthy Aging

An Early Phase 1 interventional study of Sodium lactate infusion and Exercise-induced hyperlactatemia in Aging Well and Aging, sponsored by Northern Arizona University. Not yet recruiting at 1 site in United States. Open to participants aged 20 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Northern Arizona University · Early Phase 1, Interventional, and Prevention

Phase
Early Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Study summary

The brain's primary source of fuel is glucose. Unfortunately, the brain's ability to use glucose declines during normal aging. This decline in brain glucose metabolism makes it vulnerable to cognitive impairment and Alzheimer's disease. The brain can use another fuel source - lactate - which becomes available to the brain during exercise. The investigators have discovered that when lactate fuels the brain, brain glucose metabolism also improves. Essentially, from a metabolic angle, the brain appears younger. Recently, the investigators have shown that lactate - even in the absence of exercise - stimulates this beneficial effect on the brain. The investigators propose to compare the effects of lactate in healthy young and older adults to test whether these beneficial lactate-mediated effects persist throughout the lifespan, thereby providing a blueprint to restore youthful brain glucose metabolism.

Read the detailed description

The human brain has an immense energy demand that is fueled almost exclusively by glucose. Unfortunately, the brain's ability to metabolize glucose declines with age, and this is linked to neurodegenerative diseases. Finding ways to delay, halt, or reverse brain glucose hypo-metabolism is fundamental to promoting healthy brain aging. Exercise is a well-established way to improve brain glucose metabolism. The investigators have discovered a mechanism through exercise to selectively upregulate aerobic glycolysis - the specific pathway that is responsible for the age-related decline in whole brain glucose metabolism. Aerobic glycolysis is a unique form of glucose metabolism that does not undergo oxidative phosphorylation despite sufficient oxygen availability, and is essential during brain activation, learning, and memory formation, and is highest in the early stages of life when synaptic plasticity and growth are occurring at rapid rates. Preserving aerobic glycolysis during aging protects against Alzheimer's disease. The investigators have developed an experimental model that reproducibly upregulates aerobic glycolysis in a controlled manner using infusion of lactate - an alternative and preferred fuel for the brain. Whether lactate is increased passively via infusion, or actively via exercise, aerobic glycolysis is promoted, indicating that lactate may well be the key to activating brain aerobic glycolysis during exercise. The investigators objective is to exploit this unique role of lactate to evaluate changes in brain metabolism during healthy aging. The specific aims are to test whether aerobic glycolysis can be upregulated via lactate similarly in young and older healthy individuals and determine if age influences the neurotrophic and cognitive benefits afforded by lactate in young adults. The approach is to combine our invasive cross-brain blood sampling technique with stable isotope tracers to directly quantify brain substrate metabolism during exercise and lactate infusion in healthy young adults (aged 20-30) and healthy older adults (aged 65-80). This contribution is significant since aerobic glycolysis is a metabolic signature of a young, resilient brain. Identifying ways to naturally upregulate aerobic glycolysis throughout the lifespan will provide a framework to build therapies targeted toward healthy brain aging.

The general purpose is to characterize brain metabolism during healthy aging. The investigators will do this by directly assessing brain fuel metabolism in young and older humans in response to two interventions: 1) exercise, and 2) lactate infusion, both of which challenge the brain to use alternative fuels. It is hypothesized that: 1) when made available to the brain, lactate will spare glucose for aerobic glycolysis (a beneficial metabolic pathway) and stimulate the production of neurotrophic factors in the brain, and 2) that this metabolic 'flexibility' to upregulate aerobic glycolysis will be preserved in healthy aging. Generally, the investigators will test if this youthful pattern of aerobic glycolysis can be resurrected late in life through acute exercise. The specific aims are:

  1. Determine if increasing circulating lactate - passively via infusion and actively via exercise - translates to increased brain lactate metabolism equally in otherwise healthy young and elderly humans, i.e., brain is metabolic flexibility preserved across the lifespan?
  2. Verify that increasing brain lactate metabolism causes a proportional decrease in glucose oxidation, thus providing evidence for a glucose-sparing effect of lactate, and;
  3. Determine if lactate causes a similar neurotrophic and cognitive effect in healthy young and elderly humans, i.e., does exercise permit the same brain benefits throughout the lifespan?
02

Conditions studied

  • Aging Well
  • Aging

Browse trials for

Keywords

  • brain metabolism
  • lactate
  • exercise
  • aging
03

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Meet the American College of Sports Medicine (ACSM) physical activity guidelines for moderate-intensity aerobic activity, i.e., 150+ minutes of moderate or 75+ minutes of rigorous aerobic activity.
  • The older cohort must have adhered to these physical activity guidelines for 30+ years.
  • "Good" or "Excellent" aerobic fitness category based on ACSM standardized maximal aerobic power (V̇O2max) values for age and sex.

Exclusion criteria

Exclusion Criteria:

  • Need for daily medication for chronic conditions, diagnosed heart, lung, metabolic or cerebrovascular disease, smokers, pregnancy and women in perimenopause are exclusion criteria; these will be verified with questionnaires and preliminary screening.
  • Significant carotid plaque will be excluded via ultrasound assessment.
  • Evidence of mild cognitive impairment (MCI)
  • Personal complaints of memory deficits, clinical diagnosis, or evidence from the NIH ToolBox ®V3 will be considered signs of MCI.
  • Adverse responses to maximal exercise, or an inability to complete maximal exercise during fitness screening will also be exclusion criteria.
  • known allergy to Lidocaine also cannot participate.
04

Study design

Phase
Early Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Passive lactate

    Circulating lactate will be elevated via infusion

    Biological: Sodium lactate infusion

  • Experimental
    Active lactate

    Circulating lactate will be elevated via exercise

    Other: Exercise-induced hyperlactatemia

Interventions

  • BiologicalSodium lactate infusion

    Sodium lactate will be infused to target circulating concentrations between 4-6 mmol/L

  • OtherExercise-induced hyperlactatemia

    Cycling will be performed at an intensity to increase circulating lactate to 4-6 mmol/L

05

What researchers measure

Primary outcomes

  1. Cerebral metabolism

    Lactate, glucose and oxygen metabolism via stable isotope tracers and Fick method using arterial and internal jugular venous blood sampling in combination with cerebral blood flow via ultrasound. These will be quantified as rates in grams/minute or mililiters/minute.

    Time frame: -Pre-intervention in rested state -During intervention when lactate is experimentally elevated -After recovery from intervention

Secondary outcomes

  1. Brain-specific biomarkers

    Brain-derived neurotrophic factor, secreted amyloid-b precursor protein and platelet factor-4 will be quantified from concentrations measured in blood entering and exiting the brain via sampling from arterial and internal jugular venous blood.

    Time frame: -Pre-intervention in rested state -During intervention when lactate is experimentally elevated -After recovery from intervention

  2. Cognitive function

    Several domains of cognitive function will be assessed using NIH ToolBox V3.

    Time frame: -Pre-intervention in rested state -During intervention when lactate is experimentally elevated -After recovery from intervention

06

Study locations

1 site
  • Northern Arizona University Dept of Biological Sciences
    Flagstaff, Arizona 86011, United States
07

References and documents

Individual participant data

Plan to share: No — To maintain privacy and confidentiality of participants.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07731451
Lead sponsor
Northern Arizona University
Responsible party
Travis Gibbons (Assistant Professor, Northern Arizona University) — Principal investigator
First posted
Jul 28, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Jan 1, 2028 (estimated)
Completion
Jan 1, 2029 (estimated)
Last update
Jul 28, 2026

Study contacts

TRAVIS GIBBONS, PhD
Contact
travis.gibbons@nau.edu
17785836976
Tinna Traustadottir, PhD
Contact
tinna.traustadottir@nau.edu
9282558768

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion